Φορτώνει......
The treatment with pasireotide in Cushing’s disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center
PURPOSES: Pasireotide is the first medical therapy officially approved for adult patients with Cushing’s disease (CD) experiencing failure of pituitary surgery or not candidates for surgery. The current study aimed at investigating pasireotide effects on clinical picture and metabolic profile in pat...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | J Endocrinol Invest |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Springer International Publishing
2019
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6952330/ https://ncbi.nlm.nih.gov/pubmed/31313243 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40618-019-01077-8 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|